tbuckley/cabot-search huggingface dataset:
POS1602-HPR PAIN AND CATASTROPHIZING IN RHEUMATIC DISEASES: IMPACT ON PSYCHOLOGICAL DATA AND QUALITY OF LIFE
Authors: C. Chiraz, R. Fakhfakh, N. El Amri, D. Khalifa, E. Bouajina
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Catastrophizing is a common behavior in patients with chronic pain.It is a negative cognitive-affective response to pain. It is thought to be associated with the persistence and exacerbation of chronic pain. <h3>Objectives</h3> To determine the prevalence and the associated factors of catastrophizing in rheumatic diseases(RD). <h3>Methods</h3> A cross-sectional study on patients with RD followed in the rheumatology department of hached hospital. Biological and clinical data were collected from medical records. Depression and anxiety were evaluated by the HAD scale (Hospital Anxiety and Depression scale). Quality of life was assessed by the SF-12, which is a self-assessment scale of quality of life that is a shortened version of the SF-36. Catastrophizing was assessed by the Pain catastrophizing scale (PCS). A PCS score of 30 or more represents a high level of catastrophizing. <h3>Results</h3> Our study included 60 patients with RD: 44 patients with rheumatoid arthritis(RA),12 patients with ankylosing spondylitis(SpA) and 4 patients with psoriatic arthritis (PsA). The mean age was 48.83 years (73.33% female). The mean PCS score was 31± 10.34. The prevalence of high catastrophizing(PCS ≥ 30) was 73.3% in all patients: 72.7% of patients with RA,66.7% with SpA and 100% with PsA. A high catastrophizing score was found in 91.7% of anxious patients and 95% of depressed patients.No statistically significant association of catastrophizing with age nor gender was noted. Catastrophism was significantly associated with depression, anxiety (p &lt; 10<sup>-4</sup>) and pain VAS (p=0.001). The decrease in quality of life assessed by the physical (PCS12) and mental (MCS12) components of the SF12 was significantly associated with catastrophizing (p &lt; 0.01). <h3>Conclusion</h3> In our study more than two-thirds of the population had high PCS scores with a significant correlation with pain VAS, anxiety and depression and a low quality of life score. <h3>References</h3> [1]Pain catastrophizing in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: biopsychosocial perspective and impact on health-related quality of life [2]Mateusz Wilk 1, Katarzyna Łosińska 2, Are H Pripp 3, Mariusz Korkosz 2 4, Glenn Haugeberg 5 6 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1364 VACCINATION AGAINST COVID-19 IN PARAGUAYAN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: S. Cabrera-Villalba, G. Avila, A. Amarilla, M. Zarza, E. Leiva, P. Pusineri, L. Roman, V. Valinotti, P. DE Abreu Trigueros
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> In February 2021, the first doses of COVID-19 vaccines were received in Paraguay, and rheumatic patients were the preferred population to get these vaccines. Up to December 2022 the vaccination coverage in Paraguay was 59.4%, with at least one vaccine dose. 52.4% accessed the primary scheme (two doses), while 28.6% had at least one booster dose. Only 7.1% completed the COVID-19 immunization scheme. <h3>Objectives</h3> To describe vaccination against COVID-19 in Paraguayan patients with Rheumatoid Arthritis (RA). <h3>Methods</h3> Descriptive, cross sectional, observational study, in a Paraguayan cohort of RA patients meeting ACR/EULAR2010 criteria, under follow-up in two Rheumatology reference centers, from October to December 2022. A standardized questionnaire according to the variables included (clinical, vaccination, vaccine type, number of doses) was made. Quantitative variables were presented as means and qualitative as frequencies. <h3>Results</h3> 568 patients with RA were included, 84.1% were female, mean age 55.48±13.94 years old. 23.9% patients were from Hospital de Clínicas and 76.1% from Hospital Central del Instituto de Previsión Social. The average number of received vaccinations doses was 2.54±1.19. 88.7% of patients acquired at least one dose of COVID-19 vaccine, 85% obtained two doses; and, while 60.9% of patients received the first booster, 21.2% had the second one. <h3>Conclusion</h3> In this series of Paraguayan RA patients, vaccination against COVID-19 is higher than the general population, perhaps due to priority of patients with rheumatic diseases receiving immunization, and frequent access to medical care with physician's prompt to receive vaccinations. While over 80% of patients have a complete primary schedule, and more than 60% received the first booster; only 21% have a complete immunization schedule, which is still much higher than the general population in Paraguay. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0247 WHICH PARAMETERS INFLUENCE DOMESTIC AND OCCUPATIONAL PRODUCTIVITY IN RHEUMATOID ARTHRITIS
Authors: S. Miladi, W. Belhaj, F. Alia, H. Boussaa, M. Yasmine, K. Ouanniche, S. Leila, S. Kassab, S. Chekili, K. Ben Abdelghani, A. Laatar
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Rheumatoid arthritis (RA) is a chronic rheumatism that mainly affects young adults. It has an impact on the patient's quality of life and professional abilities. <h3>Objectives</h3> The aim of this study was to evaluate the influence of RA activity, its impact, and its functional impact on patients' domestic and professional productivity. <h3>Methods</h3> We conducted a cross-sectional study over an 8-month period. Seventy adult patients diagnosed with RA for more than a year and receiving an antirheumatic therapy were interviewed. We assessed disease activity by the Disease Activity Score (DAS28), the impact of RA by the Rheumatoid Arthritis Impact of Disease (RAID) and functional impairment by the Health Assessment Questionnaire (HAQ). The impact of RA on domestic and professional productivity over the last month was assessed by the Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA). <h3>Results</h3> We noted a female predominance (63 women and 7 men) with an average age of 57.8 ±10.6 years [29-81]. At the time of the study, 13 (19%) patients were employed, 4 (6%) were unable to work because of RA while the rest were either unemployed or retired. The mean DAS28 was 3.31 ±1.13 [1.14-5.92]. The DAS28 was positively correlated with the degree of interference of RA on domestic work (p=0.001), professional work (p=0.005), and the decrease of domestic productivity (p=0.012) and professional productivity (p=0.021). Absenteeism was not influenced by RA activity (p=0.109). The average RAID score was 4.72 ±2.11 [0.6-9.48]. The RAID score was positively correlated with the degree of interference of RA on domestic work (p &lt; 0.001) and professional work (p = 0.013). No correlation was noted between the impact of RA and the decrease of domestic productivity (p=0.511), professional productivity (p = 0.109) or the absenteeism (p = 0.248). The mean value of HAQ score was 1.04 ±0.61 [0-2.60]. We noted a positive correlation between the HAQ score and the degree of interference of RA at domestic work (p &lt; 0.001) as well as the interference of RA at professional work (p = 0.012). The decrease of domestic productivity (p=0.133) and professional productivity (p=0.128) as well as the absenteeism (0.125) were not correlated with the functional impairment of RA. <h3>Conclusion</h3> According to these results, RA activity, impact, and functional impairment influenced mainly the degree of RA interference at work and domestic work. Productivity was essentially correlated with RA activity. Absenteeism was not influenced by any of the parameters studied previously. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1161 RACIAL AND GENDER - BASED DIFFERENCES IN THE PREVALENCE OF METABOLIC COMORBIDITIES AMONG PSORIATIC ARTHRITIS PATIENTS
Authors: C. R. Ng
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that develops in at least 5% of patients with psoriasis. It affects women and men equally. Obesity, diabetes, hypertension and hypercholesterolemia always affect PsA patients. <h3>Objectives</h3> To study the gender and race effect on the prevalence of metabolic comorbidities among PsA patients in Malaysia. <h3>Methods</h3> This is a restrospective study. The medical records of all PsA patients under rheumatology clinic Hospital Sultan Ismail and Hospital Pakar Sultanah Fatimah follow up from 1/1/2009 to 31/12/2022 were reviewed. Data on demography, type of skin disease, joint manifestations and past medical history were obtained and analysed using Chi Square test in SPSS. <h3>Results</h3> We identified 226 patients. 110 were male patients (male to female ratio 0.95). The Malays (128/ 226) were the majority followed by the Chinese (57/226), Indian (38/226) and others (3/226). Most of them were plaque psoriasis (181/226). The commonest joint involvement was peripheral joint (174/226), followed by axial (25/226) and both (27/226). The prevalence of metabolic comorbidities according to gender (male vs female) were: [48/110, 44% vs 57/116, 49%; p =0.407] for hypertension, [35/110, 32% vs 37/116, 32%; p=0.990} for diabetes mellitus, [63/110, 57% vs 65/116, 56%; p= 0.851] for dyslipidemia. There was no association between gender and hypertension, diabetes mellitus and dyslipidemia. The prevalence of metabolic comorbidities according to races (Malay vs non Malay) were:[58/128, 45% vs 47/98, 48%; p=0.693] for hypertension, [40/128, 31% vs 32/98, 33%; p=0.822] for diabetes mellitus, [75/128, 58% vs 53/98, 54%; p= 0.498] for dyslipidemia. There was no association between ethnicity and metabolic comorbidities. <h3>Conclusion</h3> There was no difference in the prevalence of hypertension, diabetes mellitus and dyslipidemia between the gender and races in our patient cohort. <h3>References</h3> NA. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1260 EPIDEMIOLOGICAL, CLINICAL AND CHRONOLOGICAL PROFILE OF HOSPITALIZATIONS FOR CRYSTALLINE ARTHROPATHIES IN SOUTHERN TUNISIA: A DECLINE OF 14 YEARS
Authors: M. Baklouti, Y. Mejdoub, A. Feki, H. Maamri, N. Ketata, M. Ben Jmeaa, I. Sbouii, R. Karray, J. Jdidi, S. Yaich, S. Baklouti, J. Dammak
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Crystalline arthropathies (CA) are a group of joint disorders caused by deposits of crystals in joints and the soft tissues around them. The most common type is gout. Over time, CA could lead to joint damage and even for other serious complications that could require hospitalization. <h3>Objectives</h3> This study aimed to determine the epidemiological, clinical and chronological profile of hospitalizations for CA in southern Tunisia for 14 years. <h3>Methods</h3> This was an observational retrospective study that included patients hospitalized for CA in the Hedi Chaker University Hospital Southern Tunisia, during the period 2003-2016. Data collection was done as part of the continuous survey of hospital morbidity and mortality. <h3>Results</h3> Among 148596 admissions, 187 cases were hospitalized for CA (0.12%), of which 122 subjects (64.9%) were males. The median age of hospitalized patients was 66 years (IQR=[54-75]) years. There were 96 patients (51.3%) aged&gt;65 years. The most frequent type of CA noted was gout with a global frequency of hospitalizations about 72.2% (n=135). Complications were noted among 11 patients (5.9%). They were essentially cardiovascular diseases in 5 cases (2.6%). The mean total cost of hospitalizations for CA was about 507 Tunisian Dinars (IQR=[355-718])Tunisian Dinars. The median length of hospital stay was 10 days (IQR=[6.25-15]) days. A duration&gt;10 days was statistically more frequent among patients with CA other than gout (Odds Ratio (OR)=2.12; p=0.026). Moreover, gout was statistically more frequent among patients aged less than 65 years old (OR=2.8; p=0.002). The study of the evolution profile of hospitalizations for CA showed a global trend statistically constant across the years (Rho=0.17; p=0.54). As well, there were no statistical variability of hospitalizations trends according to CA type specifically gout (Rho=0.28; p=0.32) and other CA types (Rho=0.08; p=0.77) during the survey period. <h3>Conclusion</h3> CA notably gout continue to be a relatively frequent source of hospitalizations in southern Tunisia with a stable chronological trend over the years. Thus, an adequate and a continuous management must be maintained for patients in order to control the complicated forms of these pathologies. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
Reliability and cross-country equivalence of the 8-item version of the Patient Health Questionnaire (PHQ-8) for the assessment of depression: results from 27 countries in Europe
Authors: Jorge Arias de la Torre, Gemma Vilagut, Amy Ronaldson, Jose M. Valderas, Ioannis Bakolis, Alex Dregan, Antonio J. Molina, Fernando Navarro-Mateu, Katherine Pérez, Xavier Bartoll-Roca, Matilde Elices, Víctor Pérez-Sola, Antoni Serrano-Blanco, Vicente Martín, Jordi Alonso
Journal: The Lancet Regional Health - Europe (2023)

The 8-item version of the Patient Health Questionnaire (PHQ-8) is one of the self-reported questionnaires most frequently used worldwide for the screening and severity assessment of depression. However, in some European countries its reliability is unknown, and it is unclear whether its psychometric properties vary between European countries. Therefore, the aim of this study was to assess the internal structure, reliability and cross-country equivalence of the PHQ-8 in Europe.All participants from the 27 countries included in the second wave of the European Health Interview Survey (EHIS-2) between 2014 and 2015 with complete information on the PHQ-8 were included (n = 258,888). The internal structure of the PHQ-8 was assessed using confirmatory factor analyses (CFA) for categorical items. Additionally, the reliability of the questionnaire was assessed based on the internal consistency, Item Response Theory information functions, and item-discrimination (using Graded Response Models), and the cross-country equivalence based on multi-group CFA.The PHQ-8 shows high internal consistency for all countries. The countries in which the PHQ-8 was more reliable were Romania, Bulgaria and Cyprus and less reliable were Iceland, Norway and Austria. The PHQ-8 item with highest discrimination was item 2 (feeling down, depressed, or hopeless) in 24 of the 27 countries. Measurement invariance between countries in Europe was observed from multigroup CFA at the configural, metric and scalar levels.The results from our study, likely the largest study to the date assessing the internal structure, reliability and cross-country comparability of a self-reported mental health assessment measure, shows that the PHQ-8 has an adequate reliability and cross-country equivalence across the 27 European countries included. These results highlight the suitability of the comparisons of the PHQ-8 scores in Europe. They could be helpful to improve the screening and severity assessment of depressive symptoms at the European level.This work was partially funded by CIBER Epidemiology and Public Health (CIBERESP) as part of the Intramural call of 2021 (ESP21PI05).
AB1369 FIBROMYALGIA AND INFORMATION SOURCES, THE EXAMPLE OF YOUTUBE: A CROSS-SECTIONAL ANALYSIS
Authors: A. Mouamnia, A. Desvages
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Fibromyalgia is a chronic condition affecting 2 to 8% of the population. Like any chronic disease, there is a need for information. More than one in two patients use the Internet as a source of health information. YouTube is an online video-sharing website that is consulted daily by both patients and healthcare professionals. This is the second most visited website in the world after Google. Usually, users view the top 60 most relevant videos. <h3>Objectives</h3> The aim of our study was therefore to analyse the scientific quality of fibromyalgia videos on YouTube. <h3>Methods</h3> We performed an analysis by using the French version of youtube (www.youtube.fr) using the keyword "fibromyalgia". Search parameters were left as default (i.e. ranking videos by relevance as most users do). Only videos in French were included. The Global Quality Scale (GQS) was used to assess the quality of the content. <h3>Results</h3> 60 videos were selected. Four videos were excluded: 2 duplicates and 2 videos containing only music. The main results are presented in Table 1. 37.5% (n=21) of the videos were published by academic institutions and healthcare professionals. The mean duration of the videos was 12min34. The median GQS was 4. 75% (n=42) were scientifically relevant. 62.5% (n=35) of the videos demonstrated high quality, followed by intermediate quality (19.6% (n=11)). According to the GQS, 17.0% (n=10) of the videos were of low-quality. <h3>Conclusion</h3> To the best of our knowledge, we have conducted the first study examining the scientific quality of fibromyalgia-related content on YouTube. Most of the content on YouTube relating to fibromyalgia provide useful information. Nevertheless, physicians should remind their patients to be cautious about using such a source of information. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS1161 RITUXIMAB VS. COMBINATION OF RITUXIMAB AND CYCLOPHOSPHAMIDE INDUCTION THERAPY FOR ANCA-ASSOCIATED VASCULITIS: A RETROSPECTIVE STUDY
Authors: K. Von Allwörden, S. Klapa, S. C. Werth, A. Müller, G. Riemekasten, M. Nitschke, D. Thaçi, P. Lamprecht
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> In ANCA-associated vasculitis (AAV), the use of rituximab (RTX) according to the RAVE trial [1] or RTX in combination with cyclophosphamide (CYC) according to the RITUXVAS trial [2] showed noninferiority to CYC for the induction of remission. However, there is a lack of comparative real-world data between both therapy regimens. <h3>Objectives</h3> To compare the effectiveness of RTX with combined RTX/CYC for remission induction in AAV. <h3>Methods</h3> In this comparative effectiveness retrospective monocentric study, data of 166 patients with AAV (granulomatosis with polyangiitis [GPA] n=97; microscopic polyangiitis [MPA], n=69) were analyzed. Patients were treated first-line with RTX, RTX/CYC, or CYC between January 2012 and November 2022. The primary outcome was the relapse rate at 24 months. Clinical data (BVAS, therapy) and serologic markers (creatinine, protein excretion, CRP, immunoglobulin levels) were assessed at baseline and every 6 months up to 24 months. <h3>Results</h3> Of the 166 patients, 81 received first-line RTX (RAVE), 23 RTX/CYC (RITUXVAS), and 62 CYC according to CYCLOPS [3]. At baseline, there was no difference between RAVE and RITUXVAS treatment groups with respect to disease activity (BVAS; RAVE vs. RITUXVAS: 12.07±5.69 vs. 16.12±9.85, <i>P</i>=0.2083). In AAV, treatment according to RAVE and RITUXVAS was not inferior to treatment according to CYCLOPS (Figure 1). Moreover, RTX was not inferior to RTX/CYC (HR 0.61, P=0.1356, Figure 1). Interestingly, subgroup analysis showed RAVE was slightly superior to RITUXVAS in GPA (HR: 0.48, P=0.0408, Figure 1). <h3>Conclusion</h3> In AAV, RTX and the combination of RTX/CYC were not inferior to CYC. The combination of RTX and CYC was not superior to RTX alone. <h3>References</h3> [1]Stone JH et al. <i>RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.</i> N Engl J Med. 2010 Jul 15;363(3):221-32 [2]Jones RB et al. <i>Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.</i> N Engl J Med. 2010 Jul 15;363(3):211-20. [3]de Groot K et al. <i>Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.</i> Ann Intern Med. 2009 May 19;150(10):670-80 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0076 THE THERAPEUTIC POTENTIAL OF CIRCULATING AUTOLOGOUS TISSUE HOMING EXTRACELLULAR VESICLES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS PATIENTS
Authors: G. Halpert, O. Moskovitch, A. Anaki, T. Caller, O. Gendelman, A. Watad, R. Shai, R. Popovtzer, H. Amital
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Progress has been achieved with the introduction of biologics for the management of inflammatory/autoimmune diseases such as rheumatoid arthritis (RA), however such medications induce immune suppression, which is nonselective to the pathogenesis of the disease, resulting in higher rates of infections. Therefore, there are unmet medical needs in the treatment of such diseases, which should be addressed by novel approaches. Accumulating evidence suggests that extracellular vesicles (EVs) play a role in the establishment, maintenance and modulation of autoimmune processes. <h3>Objectives</h3> In the current study, we hypothesized that isolation of circulating autologous tissue-specific homing EVs from RA patients - may improve the delivery of current FDA-approved anti-inflammatory drugs, which will be encapsulated into these EVs. The drug-loaded EVs will be injected back to the diseased subjects and will naturally find their way to the inflamed tissue. <h3>Results</h3> Indeed, we found that autologous labeled EVs, expressing joint/synovia-specific homing receptors (e.g. αVβ3 integrin), derived from blood of diseased arthritic mice (Collagen antibody-induced arthritis model), can migrate toward the inflamed synovia, using <i>in vivo</i> imaging system (IVIS). Moreover, we show that these EVs strongly expresses glucose transporter 1 (mGLUT1) which in turn, improve their therapeutic potential to be loaded with anti-inflammatory drugs using glucose-coated gold nanoparticles (GNPs). Finally, we show that EVs derived from plasma of RA patients overexpresses αVβ3 integrin and taken up by LPS/TNFα-induced activated human synovial cell line <i>in vitro</i>. <h3>Conclusion</h3> Overall, we show the potential of autologous circulating EVs of RA patients to serves as natural nano-carrier for current FDA-approved drugs. We believe that this strategy will increase the specificity and efficiency of current treatment, therefore it will reduce side effects and will improve the quality of life of RA patients and potentially other autoimmune disease patients. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.